MAGEA4 and colorectal cancer: Studies have evaluated the ability of MAGE-A4 peptide vaccines, in combination with other adjuvants, to induce specific humoral and cellular immune responses in colorectal cancer patients (Miyauchi et al. 2016; Takahashi et al. 2012).